Osteomyelitis Market Size, Share, and Industry Analysis, By Disease Type (Acute and Chronic), By Drug Type (Antibiotics, Antifungals, NSAIDs, and Others), By Route of Administration (Oral and Parenteral), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The osteomyelitis market is growing owing to the rising prevalence of the condition due to comorbid factors such as diabetes mellitus and peripheral vascular disease among the population, especially in geriatric population. Osteomyelitis is the inflammation or swelling that occurs in the bone due to open wounds, making it susceptible during surgeries, injuries, open wounds, and others.

• According to the National Institutes of Health (NIH), in 2020, globally, 310 million major surgeries are performed each year, which is around 40 to 50 million in the U.S. and 20 million in Europe.
• According to the European Review for Medical and Pharmacological Sciences, the incidence of osteomyelitis varies widely between countries. In 2019, the range has been reported to be 1.94-200 new cases per 100,000 people.

Osteomyelitis Market Driver

Increasing Prevalence of Osteomyelitis among Population to Boost Demand for Drugs

There is a global increase in the number of accidents and trauma cases, leading to open wounds and injuries. This rise in cases is resulting into rising number of surgeries and infections, fostering the demand for osteomyelitis drugs among the patient population.

• According to NIH, in 2022, the major cause of traumas and injuries leading to osteomyelitis was road accidents with overall of percentage of 69.7%.

Download Free sample to learn more about this report.

According to data published by the Ministry of Road Transport and Highways in 2022, the number of road accidents in India for 2021 were 412,432 and which increased to 461,312 witnessing a growth of 11.9% in 2022.

Osteomyelitis Market Restraint

Limited Rate of Diagnosis in Emerging Countries May Hamper Market Growth

The global burden of osteomyelitis is likely to be concentrated in countries with limited healthcare resources. The limited healthcare infrastructure and resources in emerging countries such as the Southeast Asian countries, India, Brazil, and others result into the misdiagnosis of the condition among  patients. This further increases the financial burden on the patient.

The lack of proper diagnostic procedures and equipment along with increasing misdiagnosed cases of osteomyelitis are expected to hamper the market growth. 

• According to Global Surgery, in 2019, the incidence of osteomyelitis in Sub-Saharan Africa is 43-200/100,000, with limited facilities.

Osteomyelitis Market Opportunity

Rising Number of Clinical Trials to Propel Industry Expansion

With ongoing clinical trials and present pipeline drugs for the treatment of osteomyelitis, there is a good market growth opportunity created for key players. These players can focus on the development and introduction of novel drugs and therapies.

• According to Springer Nature Switzerland AG, as of August 2024, there are 67 clinical trials and 18 pipeline drugs ongoing for osteomyelitis.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Osteomyelitis, By Key Countries/Region, 2023
• Pipeline Analysis, By Key Players
• New Product Launches, By Key Players
• Key Industry Developments (Mergers, Acquisitions, and Partnerships)
• Impact of COVID-19 on the Market

Analysis by Disease Type

Based on disease type, the market is subdivided into acute and chronic.

The acute segment accounts for a substantial market share. The growth of the segment is due to the increasing prevalence of osteomyelitis and rising risk factors including surgical wounds, posttraumatic infections, and others.

• According to a 2021 article published by the National Center for Biotechnology Information (NCBI), a nation-wide survey in Germany indicated that out of all the diagnosed cases of osteomyelitis, nearly 39.2% of the condition was acute among the Pediatric in 2019 in Germany.

Analysis by Drug Type

By drug type, the market is fragmented into antibiotics, antifungals, NSAIDs, and others.

The antibiotics segment accounts for the significant market share. Antibiotics are usually the most recommended and first line of treatment for osteomyelitis among healthcare providers as they help the rapid healing of wounds and injuries.

• According to a 2022 article published by the European Review for Medical and Pharmacological Sciences, an observational study was conducted including around 145 patients of osteomyelitis in a hospital in Italy. The study demonstrated full recovery among the 72 patients who received antibiotic therapy that accounted for nearly 50.7% of the individuals.

Analysis by Route of Administration

Based on the route of administration, the market is categorized into oral and parenteral.

The parenteral segment accounts for the largest share in the global osteomyelitis market. The standard treatment for osteomyelitis in adults includes the parental dose of antibiotics owing to the higher bioavailability and penetration of the dosage to the bones.

• According to a 2019 article published by the Diabetic Foot Journal, a study including nearly 300 patients with diabetic foot osteomyelitis was conducted which demonstrated that around 63.3% of the cases resolved clinically after one course of IV therapy. 

Analysis by Age Group

Based on age group, the market is fragmented into pediatric and adults.

Osteomyelitis commonly affect adults and the rising proportion of the geriatric population drives the market due to factors such as diabetes.

• According to a 2022 article published by the Radiological Society of North America, the overall incidence of osteomyelitis is around 21.8 cases per 100,000 adults in the U.S.

By Distribution Channel

Based on distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The increasing inpatient admissions of patients with osteomyelitis continue to increase over time. An increase in the number of hospital visits is driving the growth of hospital pharmacies segment.

• According to NIH, in 2023, the overall incidence of osteomyelitis in the U.S. was as high as 1 in 675 U.S. hospital admissions each year, or about 50,000 cases annually.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market has been studied across North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

North America accounted for the highest share of the global osteomyelitis market in 2023. The market's growth in the region is due to the increasing prevalence of the disease among pediatric and adults in the U.S. and Canada. The rising number of accidents leading to injuries and traumas further making the patients susceptible to osteomyelitis is supporting the growing number of patients in the region.

• In 2019, the National Organization for Rare Disorders estimated that two to five per 10,000 people in the U.S. get osteomyelitis each year.

The rising prevalence of osteomyelitis among the population in the U.K., Germany, France, and other European countries along with the growing focus of market players to develop and introduce novel therapies for the treatment are anticipated to drive the market growth in Europe.

• In September 2021, Locate Bio, an orthobiologics focused regenerative medicine company, raised USD 12.5 million funding for the development of its pipeline drugs which includes CognitOss, intended for the treatment of chronic osteomyelitis.

The increasing trauma and accident cases in countries such as India, China, and others along with growing healthcare infrastructure and resources in these countries are expected to foster the industry growth in the Asia Pacific.

Key Players Covered

The osteomyelitis market is fragmented with a large number of key players and providers. Few of the prominent players in the market hold a larger proportion of the market share.

The report includes the profiles of the following key players:

• Sandoz Group AG (Switzerland)
• Aenova Holding GmbH (Germany)
• Aurobindo Pharma (India)
• Lupin (India)
• Incepta Pharmaceuticals Ltd. (India)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Pfizer Inc. (U.S.)
• Asterisk Healthcare (India)

Key Industry Developments

• In March 2024, BiomX, a clinical-stage company advancing novel natural and engineered phage therapies, entered into a definitive agreement to acquire Adaptive Phage Therapeutics Inc. The acquisition is aimed toward financing of USD 50 million that will be used for the further development of its Phase II candidate, BX211 for the treatment of diabetic foot osteomyelitis.
• In March 2024, Wockhardt, a global pharmaceutical company, announced positive results from the successful utilization of an investigational antibiotic under-trial drug, Zidebactam/Cefepime for the treatment of highly drug-resistant skull bone infection and pneumonia in a renal transplant patient.